Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medrogestone is a synthetic progestin medication that functions as an agonist of the progesterone receptor, mimicking the effects of natural progesterone. It has been utilized in menopausal hormone therapy and for various gynecological disorders, including amenorrhea and menstrual irregularities. Historically, it was also employed in the treatment of endometrial cancer, breast cancer, and benign prostatic hyperplasia. Medrogestone is orally active and exhibits weak antiandrogenic, glucocorticoid, and antimineralocorticoid activities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Medrogestone.